Reproductive Panel (10 targets)
Reproductive Panel (10 targets)

[Product Name]

10 Reproductive Tract Pathogen Nucleic Acid Detection Kit (Fluorescent PCR-Chip Method)

Reproductive Panel (10 targets) CHE-STD10-201

[Packing Specifications]

12 tests / box

[Applicable Models]

Flex-Disc (Model: CH-0104) Fully Automated Nucleic Acid Analyzer

[Download Brochure]

Reproductive Panel (10 targets)Chenghui-Flex-Disc-10-Reproductive-Tract-Pathogen-Nucleic-Acid-Detection-Kit-Brochure.pdf


No Data

Testing Process

No Data

[Intended Use]

10 Reproductive Tract Pathogen Nucleic Acid Detection Kit (Fluorescent PCR-Chip Method) is a Fluorescent PCR-Chip assay intended for the qualitative detection of 10 pathogens in male urethral swabs and female cervical swabs. The pathogens that can be detected include:

  1. Mycoplasma hominis (MH), 

  2. Herpes simplex virus type 2 (HSV-II), 

  3. Ureaplasma urealyticum (UU), 

  4. Trichomonas vaginalis (TV), 

  5. Neisseria gonorrhoeae (NG), 

  6. Herpes simplex virus type 1 (HSV-I), 

  7. Mycoplasma genitalium (MG), 

  8. Haemophilus ducreyi (HD), 

  9. Gardnerella vaginalis (GV),

  10. Ureaplasma parvum (UP),

  11. Chlamydia trachomatis (CT*, RUO).


Remark: The CE  certificate is not yet acquired for the detection target of Chlamydia trachomatis (CT). Nevertheless, we are able to supply this test target  for research use only (RUO).


Challenges


Sexually transmitted infections (STIs) and reproductive tract infections (RTIs) are highly prevalent globally, representing a major clinical and public health burden for hospital outpatient departments, primary care clinics and community health centers. Conventional diagnostic approaches for reproductive tract pathogens have four core unmet needs:


Non-specific symptoms with low diagnostic accuracy and widespread empiric treatment

Most reproductive tract infections present with overlapping symptoms such as abnormal discharge, urethral irritation, itching and lower abdominal discomfort, with a high proportion of asymptomatic infections. Traditional microscopy, culture and immunoassay methods have low sensitivity, especially for fastidious pathogens like Mycoplasma genitalium, and frequently miss mixed infections. This leads to widespread empiric antibiotic use, treatment failure, recurrent infections and long-term complications such as infertility and pelvic inflammatory disease.


Long centralized testing turnaround reduces patient follow-up compliance

Traditional nucleic acid testing for reproductive pathogens relies on centralized molecular laboratories, with results typically available in 1–3 days. Patients are required to return for follow-up consultations to receive reports and treatment plans, resulting in high loss-to-follow-up rates. This not only delays timely intervention for individual patients, but also hinders public health STI transmission control.


High operational barriers limit testing access in primary care settings

Standard PCR-based testing requires dedicated molecular laboratories and certified technical personnel, resources that are largely unavailable in community clinics, grassroots medical sites and remote areas. Samples must be sent out for testing, further extending turnaround time and leaving primary care populations without access to precise reproductive tract pathogen diagnosis.


Inflexible throughput fails to match variable testing demand

Daily testing volumes in primary care settings are typically low, making high-throughput PCR instruments cost-inefficient due to idle time. Meanwhile, periodic large-scale STI screening campaigns, physical examination peaks and outpatient surges require rapid throughput expansion, creating demand for a flexible, scalable testing solution.


Core Benefits


The 10 Reproductive Tract Pathogen Nucleic Acid Detection Kit, paired with the Flex-Disc fully automated nucleic acid analysis platform, directly addresses the above outpatient and primary care pain points:


Reproductive Panel (10 targets)One-stop 10-plex pathogen profiling for accurate etiological diagnosis

A single run covers 10 high-prevalence reproductive tract pathogens, including mycoplasmas, ureaplasmas, bacteria, viruses and protozoa, with an additional Chlamydia trachomatis (CT) target available for research use only (RUO). It accurately identifies single and mixed infections, provides clear etiological evidence for clinical decision-making, reduces unnecessary antibiotic use, guides targeted therapy and lowers the risk of recurrent infections and long-term complications.


Results in around 40 minutes to support same-visit clinical decision-making

Total testing time is around 40 minutes, with only 1 minute of hands-on sample loading. Patients receive full diagnostic results within a single outpatient visit, eliminating the need for return trips, improving treatment compliance and protecting patient privacy. It enables clinicians to formulate targeted treatment plans immediately, greatly improving outpatient diagnostic efficiency.


Low-barrier POCT deployment to expand primary care testing access

The fully automated closed system requires no standardized molecular laboratory or specialized technical staff, and can be operated by frontline medical workers after brief training. It can be deployed directly in community health centers, grassroots clinics, physical examination centers and remote medical sites, making precise reproductive tract pathogen testing accessible to more patients at the point of care.


Modular scalable throughput to adapt to diverse scenario requirements

Powered by the Flex-Disc platform, each independent testing module processes one sample at a time, with a single control terminal supporting wireless connection to up to 8 modules simultaneously. Facilities can scale the number of modules according to actual sample volume: a single module meets routine primary care demand, while multi-module parallel operation handles physical examination peaks and public health screening campaigns, balancing operational cost and testing capacity.


Core Product Advantages


Outpatient and primary care-aligned 10-plex pathogen panel

The panel covers 10 clinically prevalent reproductive tract pathogens: Mycoplasma hominis (MH), Ureaplasma urealyticum (UU), Ureaplasma parvum (UP), Mycoplasma genitalium (MG), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), Herpes simplex virus type 1/2 (HSV-I/II), Haemophilus ducreyi (HD) and Gardnerella vaginalis (GV). An additional Chlamydia trachomatis (CT) target is available for research use only (RUO). The panel fully covers the diagnostic needs of common vaginitis, urethritis and STIs, with an optimal balance of comprehensiveness and cost-effectiveness for outpatient and primary care settings.


Fully automated closed sample-to-result workflow

Leveraging proprietary centrifugal microfluidic technology, the kit integrates two gold-standard workflows — silica membrane-based nucleic acid extraction and multiplex real-time qPCR — within a single enclosed disposable cartridge. Only 1 minute of manual pipetting is required, with no professional molecular operation expertise needed, delivering true load-and-go detection.


Modular scalable throughput design for flexible deployment

Compatible with the Flex-Disc (Model: CH-0104) Fully Automated Nucleic Acid Analyzer, each testing module processes 1 sample per run with full results available in around 40 minutes. One main control terminal can connect wirelessly to up to 8 testing modules, supporting random access and parallel testing to flexibly match sample volumes from small primary clinics to hospital outpatient departments.

Reproductive Panel (10 targets)


Lyophilized reagents for room-temperature storage and transport

With our self-developed PCR reagent lyophilization process, pre-embedded lyophilized reagent beads in the microfluidic chip enable room-temperature storage and transportation, eliminating cold chain reliance. This greatly reduces storage and logistics costs for primary care facilities and remote sites, supporting large-scale public health deployment.


Zero cross-contamination closed cartridge system

Each sample is processed in an individual sealed disposable cartridge, with amplification products never exposed to the external environment. This design fundamentally eliminates aerosol cross-contamination, reduces on-site quality control requirements, and ensures stable, reliable results even in non-laboratory primary care settings.


CE-compliant with validated dual sample type compatibility

The assay is fully validated for male urethral swab and female cervical swab samples. All 10 core targets are CE-marked, with Chlamydia trachomatis (CT) designated for research use only (RUO), meeting regulatory requirements for clinical diagnosis, public health screening and research applications across global markets.